["{\n\"step_by_step_thinking\": \"Since there is no mention of tremelimumab in the provided documents, we cannot determine if it improves survival for mesothelioma patients. However, since one of the documents discusses immunotherapy and its limitations in treating malignant melanomas, we can conclude that immunotherapy, including monoclonal antibodies like tremelimumab, has not been proven to be curative or significantly impact survival for mesothelioma patients.\",\n\"answer_choice\": \"B\"\n}"]